- Obagi Medical launches Retinol + PHA Refining Night Cream.
- Clinical trials show significant improvements in skin texture and tone.
- Product available through professional channels and on Obagi.com from May 5, 2025.
Obagi Medical, a subsidiary of Waldencast plc (WALD, Financial) and the fastest-growing professional skincare brand in the U.S. in 2024, has announced the launch of its latest product, the Retinol + PHA Refining Night Cream. This premium skincare product, priced at $135, aims to combine Entrapped Retinol with Polyhydroxy Acid (PHA) Gluconolactone in a slow-release formula.
The launch comes after promising results from a clinical study showing a 29% increase in skin smoothness and a 10% improvement in skin tone evenness after just four weeks. Notably, 90% of users reported visibly smoother skin texture, while an equal percentage observed reduced blemish appearances.
Formulated with eight additional ingredients such as Sodium Hyaluronate, Vitamin E, Squalane, and Glycerin, the Retinol + PHA Refining Night Cream will first be available through professional channels, before becoming accessible on Obagi.com starting May 5, 2025.
This product launch marks a significant step for Waldencast (WALD, Financial) in addressing retinol-sensitive consumers who often face challenges with traditional retinol treatments. By employing a slow-release delivery system with a gentler exfoliant, the product aims to expand its user base to include individuals with sensitive skin.
